60
Participants
Start Date
January 1, 2017
Primary Completion Date
January 31, 2022
Study Completion Date
January 31, 2022
University of Alabama at Birmingham, Birmingham
Collaborators (1)
Pfizer
INDUSTRY
National Heart, Lung, and Blood Institute (NHLBI)
NIH
University of Alabama at Birmingham
OTHER